Syon Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.8M Sell
12,819
-51
-0.4% -$51.7K 0.59% 35
2025
Q4
$13.8M Sell
12,870
-383
-3% -$366K 0.69% 30
2025
Q3
$10.1M Buy
13,253
+1,212
+10% +$902K 0.54% 36
2025
Q2
$9.39M Buy
12,041
+371
+3% +$288K 0.62% 31
2025
Q1
$9.64M Buy
11,670
+1,171
+11% +$974K 0.78% 30
2024
Q4
$8.11M Sell
10,499
-763
-7% -$632K 0.73% 28
2024
Q3
$9.98M Buy
11,262
+127
+1% +$114K 0.88% 21
2024
Q2
$10.1M Sell
11,135
-15
-0.1% -$12K 0.93% 19
2024
Q1
$8.67M Sell
11,150
-10,426
-48% -$7.42M 0.82% 21
2023
Q4
$12.6M Buy
21,576
+12,062
+127% +$7.04M 0.53% 36
2023
Q3
$5.11M Buy
+9,514
New +$4.9M 0.64% 28

Other funds holding LLY

Syon Capital's LLY Position: Q1 2026 in Review

Syon Capital reduced its Eli Lilly (LLY) stake by 0.4% in Q1 2026, selling an estimated $51.7K and leaving 12,819 shares worth $11.8M. The position accounts for 0.59% of the portfolio, ranked #35.

Syon Capital first reported a position in LLY in Q3 2023 and has held it in 11 quarters since. The position peaked at $13.8M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Syon Capital held 12,819 shares of Eli Lilly worth $11.8M as of Q1 2026.
  • Syon Capital sold 51 Eli Lilly shares in Q1 2026, an estimated $51.7K.
  • Eli Lilly made up 0.59% of Syon Capital's portfolio in Q1 2026, its #35 holding.
  • Syon Capital first reported a position in Eli Lilly in Q3 2023 and has held it in 11 quarters since.
  • Syon Capital's Eli Lilly position peaked at $13.8M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Syon Capital's 13F filing for Q1 2026, filed 13 May 2026.